CClinicalTrials.gg
Status unknownNCT03309501Updated Nov 9, 2017

Tong-Luo-Qu-Tong Plaster for KOA: a Randomised, Double-blind, Parallel Positive Control, Multi-center Clinical Trial

A Phase 3 interventional study of Tong-Luo-Qu-Tong Plaster and Qi-Zheng-Xiao-Tong Plaster in Knee Osteoarthritis and Chronic Musculoskeletal Disease, sponsored by Shanghai University of Traditional Chinese Medicine. Status unknown at 1 site in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-11-09.

Sponsored by Shanghai University of Traditional Chinese Medicine · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
2,000
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Study summary

Knee osteoarthritis(OA), also known as degenerative arthritis, have affected a lot of people. Patients with severe osteoarthritis frequently develop one or more of the typically following symptoms: joint pain, stiffness, activity with joint friction noise, limited mobility, such as difficulty walking and climbing. Now there are many western medicine treatments including symptom relief and joint cartilage protective agents for OA, but the results have not yet satisfied. TCM treatment of osteoarthritis has remarkable curative effect and unique advantage.Tong-Luo-Qu-Tong Plaster is a common method to treat osteoarthritis of the knee for thousands of years in China. It lacked a large sample randomised, double-blind, parallel positive controlled, multicenter clinical trial, and the clinical evidence of Tong-Luo-Qu-Tong Plaster for Knee Osteoarthritis need to be further completed.

Read the detailed description

A randomised, double-blind, parallel positive controlled, multicenter clinical trial will be conducted to assess the effectiveness and safety of Tong-Luo-Qu-Tong Plaster on patients with knee osteoarthritis. A total of 2000 patients with knee osteoarthritis will be recruited and randomly allocated into experimental group(1500) or control group(500). Each patient will undergo a 2-week treatment with herbal patches for one session per day.The western Ontario and McMaster universities osteoarthritis index (WOMAC) as objective indicators of efficacy is the primary efficacy endpoint of the study.The secondary outcome measures are the changes in TCM syndrome quantitative score, Visual Analog Scale/Score (VAS) score of pain, and the effective time of pain relief of drug from the baseline to 1 week, 2 weeks' follow-up.

02

Conditions studied

  • Knee Osteoarthritis
  • Chronic Musculoskeletal Disease

Keywords

  • Knee osteoarthritis
  • Randomised Double-blind Controlled trial
  • Tong-Luo-Qu-Tong Plaster
03

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Participants who have symptomatic knee osteoarthritis, diagnosis of KOA was based on criteria developed by the American College of Rheumatology(ACR) in 1986
  • The differentiation standard of the arthralgia syndrome of traditional Chinese medicine(TCM): Referring to the Guidelines on the clinical research of Chinese medicine new drugs(2002)
  • The visual analog scale score is no less than 30 mm.
  • The patient is older than or equal to 40 years old
  • All the patients signed informed consent form before study begins

Exclusion criteria

Exclusion Criteria:

  • Hormone therapy was used in the first month of screening
  • Arthroscopy and intra-articular injection was performed on the knee joint which is going to be evalued during the first three months of screening.
  • There is a history of trauma or surgery in the knee joint six months before screening or participants who a history of lessmore than three trauma or surgical procedures in the knees
  • Participants who have knee arthroplasty, lumbar spinal stenosis, ankylosing spondylitis, rheumatic arthritis, rheumatoid factor positive(>40), eallergic constitution and mental disorder will be excluded from the trial
  • Patients has severe diseases and complications such as severe diabetes, serious liver and kidney disease, malignant tumors, infectious diseases or complications affecting the knee joints
  • Pregnant,lactating women
  • Subjects are participating in or have participated in other clinical trials in the first three months.
  • Subjects cannot stop using the drugs immediately with a long-term use of other related drugs.
  • Combined with severe primary diseases such as hepatic renal functionand hematopoietic system, such as liver function (ALT≧1.5×ULN), and kidney function(AST≧1.5×ULN)
04

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,000 participants (estimated)

Study arms

  • Experimental
    Tong-Luo-Qu-Tong Plaster group

    Intervention: Tong-Luo-Qu-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses

    Drug: Tong-Luo-Qu-Tong Plaster

  • Active comparator
    Qi-Zheng-Xiao-Tong Plaster group

    Intervention: Qi-Zheng-Xiao-Tong Plaster, daily 1 time, conventional treatment lasted for 14 days as two courses

    Drug: Qi-Zheng-Xiao-Tong Plaster

Interventions

  • DrugTong-Luo-Qu-Tong Plaster

    for 14 days as two period of treatment, daily 1 time.

  • DrugQi-Zheng-Xiao-Tong Plaster

    for 14 days as two period of treatment, daily 1 time

05

What researchers measure

Primary outcomes

  1. WOMAC scores

    Western Ontario and McMaster universities osteoarthritis index, ranges 0-96. Higher values represent a worse outcome.

    Time frame: from baseline to 2 weeks

Secondary outcomes

  1. TCM syndrome quantitative scores

    Referring to the Guidelines on the clinical research of Chinese medicine new drugs(2002), the TCM syndrome quantitative score ranges 0-21.Higher values represent a worse outcome.

    Time frame: from baseline to 2 weeks

  2. Visual analogue pain scale

    Visual Analog Scale /Score ranges 0-10.Higher values represent a worse outcome.

    Time frame: from baseline to 2 weeks

  3. On effective time of pain relief of drug

    The effective time of pain relief was the time of 10mm was reduced for the first time according to the daily VAS score of the patient's diary.

    Time frame: In 2 weeks

06

Study locations

1 of 1 sites recruiting
  • Longhua Hospital, Shanghai University of TCM
    Shanghai, Shanghai 200032, China
    • Xuejun Cui, Dr · Contact · 13917715524@139.com · 021-64385700
    • Yongjun Wang, Dr · Principal investigator
    Recruiting
07

References and documents

Publications

  • Xu BP, Yao M, Tian ZR, Zhou LY, Yang L, Li ZJ, Zhu S, Wang XT, Lan JH, Wang YJ, Cui XJ. Study on efficacy and safety of Tong-luo Qu-tong plaster treatment for knee osteoarthritis: study protocol for a randomized, double-blind, parallel positive controlled, multi-center clinical trial. Trials. 2019 Jun 24;20(1):377. doi: 10.1186/s13063-019-3481-6. PubMed 31234919 ↗
08

Registry details

Key details

Study ID
NCT03309501
Lead sponsor
Shanghai University of Traditional Chinese Medicine
Collaborators
Shanghai Zhongshan Hospital, Suzhou Hospital of Traditional Chinese Medicine, Luoyang Osteopathy hospital of Henan, Hubei Hospital of Traditional Chinese Medicine, Liaoning University of Traditional Chinese Medicine, The Second Hospital of Nanjing Medical University, The Fourth Central Hospital of Tianjin
Responsible party
Cui xuejun (associate professor, Shanghai University of Traditional Chinese Medicine) — Principal investigator
First posted
Oct 13, 2017
Start date
Sep 12, 2017
Primary completion
Dec 20, 2019 (estimated)
Completion
Sep 20, 2020 (estimated)
Last update
Nov 9, 2017

Study contacts

Xuejun Cui, Doctor
Contact
13917715524@139.com
021-64385700 ext. 1309
Yongjun Wang, Doctor
principal investigator · Longhua Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion